5AM Ventures

• Read Me Dianthus Therapeutics Strengthens Leadership Team with Appointment of Susan Kalled, Ph
• D
• , as Chief Scientific Officer
• Read Me IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma
• Read Me Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
• Read Me Wildcat Discovery Signs Joint Development Agreement with BMW Group to Speed Next Generation Battery Technology to the Market
• Read Me Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List

Pushing the healthcare industry forward

• $ 0 B UNDER MANAGEMENT We’re a life science venture capital firm founded in 2002 and currently investing $450M from 5AM Ventures VII and $300M from 5AM Opportunities II

We’re a life science venture capital firm founded in 2002 and currently investing $450M from 5AM Ventures VII and $300M from 5AM Opportunities II

• 0 PORTFOLIO COMPANIES Our focus is biopharmaceuticals, drug delivery technologies and life science instruments

Our focus is biopharmaceuticals, drug delivery technologies and life science instruments

• 0 ONGOING CLINICAL TRIALS Historically our portfolio companies have had over 80,000 patients enrolled across 8,000 test sites in clinical trials

Historically our portfolio companies have had over 80,000 patients enrolled across 8,000 test sites in clinical trials